Neoadjuvant chemotherapy (NC) should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer (MIUC) of the bladder – A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process | Zendy

Jo-An Seah | Zendy; Srikala S. Sridhar | Zendy; Lori Wood | Zendy; Normand Blais | Zendy; Scott North | Zendy; Yasmin Rahim | Zendy; Dean Ruether | Zendy; Peter C. Black | Zendy; Alexandre R. Zlotta | Zendy

Open Access

Neoadjuvant chemotherapy (NC) should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer (MIUC) of the bladder – A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process

Author(s) -

Jo-An Seah,

Srikala S. Sridhar,

Lori Wood,

Normand Blais,

Scott North,

Yasmin Rahim,

Dean Ruether,

Peter C. Black,

Alexandre R. Zlotta

Publication year - 2013

Publication title -

canadian urological association journal

Language(s) - English

Resource type - Journals

eISSN - 1920-1214

pISSN - 1911-6470

DOI - 10.5489/cuaj.1506

Subject(s) - bladder cancer , medicine , genitourinary system , urothelial cancer , chemotherapy , oncology , cisplatin , neoadjuvant therapy , cancer , gynecology , urology , breast cancer

Neoadjuvant chemotherapy (NC) improves overall survival in patients with resectable muscle-invasive urothelial cancer of the bladder (MIBC). However uptake of NC in Canada is dis-appointingly low. Following a detailed literature review and in consultation with urologic oncology, the Canadian Association of Genitourinary Medical Oncologists (CAGMO) has developed a consensus statement for the use of NC in MIBC. Our primary goal is to increase the uptake of NC for MIBC in Canada and improve patient outcomes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research